S. Gurbuz

发表

Study description and baseline characteristics of the population enrolled in a multinational, observational study of teriparatide in postmenopausal women with osteoporosis: the Asia and Latin America Fracture Observational Study (ALAFOS)

R. Burge, S. Ish-shalom, Huilin Yang, 2019, Current medical research and opinion.

The Effect of Teriparatide Treatment on the Risk of Fragility Fractures in Postmenopausal Women with Osteoporosis: Results from the Asian and Latin America Fracture Observational Study (ALAFOS)

S. Ish-shalom, Huilin Yang, Z. Belaya, 2021, Calcified tissue international.

Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease‐Modifying Antirheumatic Drug Treatment

D. M. van der Heijde, C. Zerbini, S. de Bono, 2017, Arthritis & rheumatology.

Decision tree analyses of key patient characteristics in Middle Eastern/North African and Latin American men treated with long-acting and short-acting PDE5 inhibitors for erectile dysfunction

E. Rubio-Aurioles, C. Henneges, A. El-Meliegy, 2015, Current medical research and opinion.

An observational study to assess back pain in patients with severe osteoporosis treated with teriparatide versus antiresorptives: An Indian subpopulation analysis

R. Malhotra, K. See, H. Chhabra, 2015, Indian journal of endocrinology and metabolism.

LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial

D. D’Alessio, Z. Milicevic, Melissa K Thomas, 2022, The Lancet.

A 6-month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Middle Eastern and North African men with erectile dysfunction

T. Hussein, D. Rabah, Y. Lei, 2013, Current medical research and opinion.

Effects of teriparatide in Chinese and Caucasian women with osteoporosis: bridging study on efficacy

Yun Chen, S. Gurbuz, Yujie Li, 2019, Clinical interventions in aging.

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA

J. Rosenstock, J. Frias, Z. Milicevic, 2023, The Lancet.

A systematic review on the use of daily subcutaneous administration of teriparatide for treatment of patients with osteoporosis at high risk for fracture in Asia

K. Yang, H. Sowa, Zhiyong Zhang, 2014, Osteoporosis International.

Association between teriparatide treatment persistence and adherence, and fracture incidence in Taiwan: analysis using the National Health Insurance Research Database

F. Hsiao, R. Burge, J. Tsauo, 2016, Osteoporosis International.

Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.

L. Kaplan, J. Frias, Z. Milicevic, 2023, The New England journal of medicine.